Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-08-31 Governance Information
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
子公司管理制度
Governance Information Classification · 95% confidence The document is titled as a 'Subsidiary Management System' issued by the board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details internal governance rules, management control, audit supervision, and information disclosure requirements for subsidiaries. The document includes board meeting approval details and is a formal governance policy document rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content aligns with governance information about internal rules and board structure. Therefore, the document best fits the 'Governance Information' category (CGR). The document length is 2423 characters, which is sufficient for a substantive governance document but not a full annual or interim report.
2025-08-31 Chinese
累积投票实施细则
Governance Information Classification · 95% confidence The document is a detailed announcement of the implementation rules for cumulative voting for the election of directors at Chengdu Oukang Pharmaceutical Co., Ltd. It includes procedural details, voting methods, nomination processes, and election conditions for directors. The document is not a financial report, earnings release, or audit report. It is not a simple announcement of voting results but rather a comprehensive internal governance document related to board elections. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3240 characters, which is sufficient for a detailed governance report rather than a brief announcement or notice. Therefore, the classification is CGR with high confidence.
2025-08-31 Chinese
第四届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 4th Board of Directors of Chengdu Oukang Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various internal governance documents and policies. The content focuses on board decisions, governance structure changes, appointment of a securities affairs representative, and the proposal to convene a shareholders' meeting. There is no financial data, earnings information, or audit report content. The document is not a report itself but an official announcement of board meeting resolutions and governance matters. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (6255 characters) and detailed content support this classification with high confidence.
2025-08-31 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled as a "Profit Distribution Management System" of Chengdu Oukang Pharmaceutical Co., Ltd., detailing the company's internal policies and procedures regarding profit distribution, dividend policies, decision-making processes, and supervisory mechanisms. It includes detailed rules on dividend distribution, cash dividend policies, board and shareholder meeting roles, and disclosure requirements. The document is a formal announcement of the company's internal management system related to profit distribution, not a financial report or earnings release. It is not a report of voting results, nor a regulatory filing or certification. The document is a governance-related policy document issued by the board, describing internal rules and governance practices related to profit distribution. Therefore, it fits best under the category of Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, not just an announcement or notice, so it is not RPA or RNS.
2025-08-31 Chinese
独立董事工作制度
Governance Information Classification · 100% confidence The document is a detailed internal governance policy titled 'Independent Director Work System' issued by the board of Chengdu Oukang Pharmaceutical Co., Ltd. It outlines the qualifications, duties, nomination, and operational procedures for independent directors in compliance with Chinese securities laws and Beijing Stock Exchange rules. It includes voting results from a board meeting and detailed governance rules but does not contain financial statements, earnings data, or audit results. It is a governance-related document focused on board structure and director responsibilities rather than a financial report or announcement. Therefore, it fits the category of Governance Information (CGR). The document length (9170 characters) and content confirm it is the full policy text, not a brief announcement or certification.
2025-08-31 Chinese
拟续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (audit firm) for the fiscal year 2025. It details the audit firm's background, qualifications, independence, audit fees, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, nor is there a detailed audit opinion or results. The document is relatively short (2970 characters) and serves as a formal announcement of the intention to reappoint the auditor, pending shareholder approval. This fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. It is not a report publication announcement since it contains substantive information about the audit firm and the reappointment process, not just a notice of report availability. FY 2025
2025-08-31 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.